About ARTBIO
ARTBIO is a clinical-stage radiopharmaceutical company redefining cancer care by creating a new class of alpha radioligand therapies (ARTs) using the optimal alpha-precursor isotope (Pb-212) paired with tumor-specific targets. Its proprietary AlphaDirect™ technology enables distributed manufacturing and reliable delivery of ARTs, with lead program AB001 currently in first-in-human trials for metastatic castration-resistant prostate cancer.
Company details
Funding
Total raised
$245M
Last stage
Series B
Investors
Founders
Roy H. Larsen
PhD; co-invented Xofigo (acquired by Bayer via Algeta), the first-ever metabolically targeted alpha therapy; long-standing researcher at the University of Oslo and Norway's Radium Hospital.
Øyvind Bruland
MD; co-invented Xofigo with Roy Larsen; veteran radiopharmaceutical researcher based in Oslo, Norway; collaborated with F-Prime and Radforsk to co-found ARTBIO in 2021.
Emanuele Ostuni
PhD; formerly Head of Europe for Cell and Gene Therapy at Novartis Oncology; joined ARTBIO in early 2022 to build the company and advance its proprietary technology.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.